Aptose Biosciences (APTO) Revenue & Revenue Breakdown
Aptose Biosciences Revenue Highlights
Aptose Biosciences Revenue by Period
Aptose Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-05-31 | - | 100.00% |
| 2013-05-31 | - | 100.00% |
| 2012-05-31 | - | 100.00% |
| 2011-05-31 | - | -100.00% |
| 2010-05-31 | $124.16K | -26.45% |
| 2009-05-31 | $168.81K | 292.36% |
| 2008-05-31 | $43.02K | -56.99% |
| 2007-05-31 | $100.02K | 316.75% |
| 2006-05-31 | $24.00K | 380.11% |
| 2005-05-31 | $5.00K | -98.88% |
| 2004-05-31 | $446.69K | 834.06% |
| 2003-05-31 | $47.82K | 100.00% |
| 2002-05-31 | - | -100.00% |
| 2001-05-31 | $1.00K | 49.88% |
| 2000-05-31 | $667.40 | -99.02% |
| 1999-05-31 | $67.82K | -1.21% |
| 1998-05-31 | $68.65K | -5.38% |
| 1997-05-31 | $72.56K | - |
Aptose Biosciences generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Aptose Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $712.21K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-05-31 | - | 100.00% |
| 2014-02-28 | - | 100.00% |
| 2013-11-30 | - | 100.00% |
| 2013-08-31 | - | 100.00% |
| 2013-05-31 | - | 100.00% |
| 2013-02-28 | - | 100.00% |
| 2012-11-30 | - | 100.00% |
| 2012-08-31 | - | 100.00% |
| 2012-05-31 | - | 100.00% |
| 2012-02-29 | - | 100.00% |
| 2011-11-30 | - | 100.00% |
| 2011-08-31 | - | 100.00% |
| 2011-05-31 | - | 100.00% |
| 2011-02-28 | - | 100.00% |
| 2010-11-30 | - | 100.00% |
| 2010-08-31 | - | -100.00% |
| 2010-05-31 | $-474.84 | -116.64% |
| 2010-02-28 | $2.85K | -96.18% |
| 2009-11-30 | $74.69K | 66.95% |
| 2009-08-31 | $44.74K | -47.56% |
| 2009-05-31 | $85.31K | 69.23% |
| 2009-02-28 | $50.41K | 63.06% |
| 2008-11-30 | $30.92K | 100.00% |
| 2008-08-31 | - | -100.00% |
| 2008-05-31 | $11.93K | 296.21% |
| 2008-02-29 | $3.01K | - |
Aptose Biosciences generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Aptose Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CTMX | CytomX Therapeutics | $101.21M | $25.11M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| ADAP | Adaptimmune Therapeutics | $60.28M | $128.37M |
| FBIO | Fortress Biotech | $59.66M | $13.03M |
| AFMD | Affimed | $8.28M | $155.00K |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| AGLE | Spyre Therapeutics | $2.33M | - |
| TFFP | TFF Pharmaceuticals | $733.87K | $650.22K |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| GANX | Gain Therapeutics | $55.18K | - |
| CRVS | Corvus Pharmaceuticals | - | - |
| APTO | Aptose Biosciences | - | - |
| MBIO | Mustang Bio | - | - |
| LBPH | Longboard Pharmaceuticals | - | - |
| LPTX | Leap Therapeutics | - | - |
| TIL | Instil Bio | - | - |
| INAB | IN8bio | - | - |
| NLTX | Neurogene | - | - |
| ACHL | Achilles Therapeutics | - | - |
| ONCT | Oncternal Therapeutics | - | - |
| LTRN | Lantern Pharma | - | - |
APTO Revenue FAQ
What is Aptose Biosciences’s yearly revenue?
Aptose Biosciences's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. APTO's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Aptose Biosciences’s quarterly revenue?
Aptose Biosciences's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). APTO's quarterly revenue for Q4 2023 was $712.21K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Aptose Biosciences’s revenue growth rate?
Aptose Biosciences's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.